07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Additional Phase III data

Additional pooled data from 993 patients with cIAIs in a pair of identical, double-blind, double-dummy, international Phase III trials showed that 1.5 g IV ceftolozane/tazobactam every 8 hours plus 0.5 g IV metronidazole for 4-14...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Additional Phase III data

Additional pooled data from 1,083 patients with cUTI in a pair of identical, double-blind, international Phase III trials showed that 1.5 g IV ceftolozane/tazobactam every 8 hours for 7 days led to a composite cure...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III data

Last month, Cubist reported that IV ceftolozane/tazobactam met the FDA- and EMA-defined primary endpoints of non-inferiority to IV levofloxacin in a pair of identical Phase III trials to treat complicated urinary tract infection (cUTI) (see...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III data

Cubist expects to report top-line data late this month from a pair of Phase III trials evaluating ceftolozane/tazobactam to treat complicated intra-abdominal infections (cIAI). Cubist plans to submit an NDA to FDA in 1H14 and...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

Ceftolozane/tazobactam: Phase III started

Cubist began the open-label, U.S. and Australian Phase III VECTOR trial comparing 3,000 mg IV ceftolozane/tazobactam every 8 hours vs. 4,500 mg piperacillin/tazobactam every 6 hours in about 300 patients. The product is in Phase...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase III started

Cubist began a double-blind, double-dummy, international Phase III trial to compare 1,500 mg IV CXA-201 every 8 hours in combination with 500 mg IV metronidazole every 8 hours for 4-14 days vs. 1,000 IV meropenem...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase III started

Cubist began a double-blind, international Phase III trial to compare 1,500 mg IV CXA-201 given every 8 hours for 7 days vs. IV levofloxacin in about 775 patients. The company expects to begin a second...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

CXA-201: Phase II data

Top-line data from a double-blind, international Phase II trial in 122 patients showed that 1.5 g thrice-daily IV CXA-201 plus metronidazole led to a comparable clinical cure rate at the TOC visit 7-14 days after...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

CXA-201: Phase II started

Cubist began a double-blind, international Phase II trial to compare CXA-201 plus metronidazole vs. meropenem plus placebo in 120 patients. Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan) granted worldwide rights outside of certain Asia-Pacific and...